Dieter Hörsch, MD: For Patients With Bronchopulmonary Neuroendocrine Tumors, Lanreotide Autogel May Be Beneficial
ESMO Congress 2021
Dieter Hörsch, MD, of Germany’s Central Clinic in Bad Berka, discusses phase III results from the SPINET trial, the largest prospective study to date of the somatostatin analog lanreotide autogel. The study suggests that this agent may prove to be an appropriate treatment option for patients with somatostatin receptor–positive bronchopulmonary neuroendocrine tumors, especially typical carcinoids (Abstract 1096O).
The ASCO Post Staff
Neeraj Agarwal, MD, of Hunstman Cancer Institute at the University of Utah, discusses efficacy and safety results from the COSMIC-021 study, in which cabozantinib plus atezolizumab demonstrated clinically meaningful activity and a manageable safety profile in patients with metastatic castration-resistant prostate cancer. The findings support a phase III study of these agents vs a second line of novel hormonal therapy (Abstract LBA24).
The ASCO Post Staff
Gerhardt Attard, MD, PhD, of The Royal Marsden NHS Foundation Trust, discusses findings that show 2 years of abiraterone acetate plus prednisolone-based treatment improves metastasis-free and overall survival in men with high-risk nonmetastatic prostate cancer. The data suggest this combination regimen might be considered a new standard of care (Abstract LBA4).
The ASCO Post Staff
Hope S. Rugo, MD, of the University of California, San Francisco, discusses phase III results from the KEYNOTE-355 study of pembrolizumab plus chemotherapy, which improved overall survival vs chemotherapy alone in patients with previously untreated locally recurrent, inoperable, or metastatic triple-negative breast cancer whose tumors expressed PD-L1 (Abstract LBA16).
The ASCO Post Staff
Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, discusses phase III results from the PEACE-1 study, which showed that androgen-deprivation therapy plus docetaxel and abiraterone provided 2.5 years of additional time without radiographic disease progression or death and 1.5 additional years of survival in men with de novo high-volume metastatic castration-sensitive prostate cancer (Abstract LBA5).
The ASCO Post Staff
Robin Cornelissen, MD, PhD, of Erasmus University in Rotterdam, discusses phase II findings from the ZENITH20-4 study, which explored the question of whether poziotinib could benefit patients whose newly diagnosed non–small cell lung cancer harbors EGFR and HER2 exon 20 mutations. Potentially, this novel tyrosine kinase inhibitor may fill an unmet medical need (Abstract LBA46).
